Write in a clean editor, then format for Kidney Medicine in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Kidney Medicine is a peer-reviewed journal published by Elsevier, covering Dialysis and Renal Disease Management, Chronic Kidney Disease and Diabetes, Renal Diseases and Glomerulopathies.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, Kidney Medicine 12 (2023) 45–58.
Formats any DOI in Kidney Medicine style. No sign-up. |
| Publishes research in | Dialysis and Renal Disease Management Chronic Kidney Disease and Diabetes Renal Diseases and Glomerulopathies Acute Kidney Injury Research Renal Transplantation Outcomes and Treatments |
| ISSN | 2590-0595 |
| Citation impact (2-yr) | 1.76 |
| h-index | 46 |
| i10-index | 352 |
| Total citations | 11,370 |
| Article processing charge | $2,400 |
| Open access | Yes |
| Top institutions publishing here | Johns Hopkins University |
| Journal website | www.journals.elsevier.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
RATIONALE & OBJECTIVE: Chronic kidney disease (CKD)-associated pruritus, generalized itching related to CKD, affects many aspects of hemodialysis patients' lives. However, information regarding the relationship between pruritus and several key outcomes in hemodialysis patients remains limited. STUDY DESIGN: Prospective cohort. SETTING & PARTICIPANTS: 23,264 hemodialysis patients from 21 countries in the Dialysis Outcomes and Practice…
should be balanced against and may outweigh the risk of NSF. Dialysis initiation or alteration is likely unnecessary based on group II or group III GBCM administration.
Rationale & Objective Chronic kidney disease–associated pruritus (CKD-aP) in patients treated by hemodialysis (HD) impairs quality of life (QoL). Difelikefalin, a selective κ-opioid receptor agonist, decreased the intensity of CKD-aP in patients undergoing HD. This pooled analysis evaluated difelikefalin's efficacy and the itch-related QoL overall and in subgroups defined by demographics or disease characteristics. Study…
Alport syndrome affects up to 60,000 people in the United States. The proposed reclassification of thin basement membrane nephropathy and some cases of focal segmental glomerulosclerosis as Alport syndrome could substantially increase the affected population. The reclassification scheme categorizes Alport syndrome as 3 distinct diseases of type IV collagen α3/4/5 based on a genetic evaluation:…
